RT Journal Article
SR Electronic
T1 Clinical Validation of a Novel T-cell Receptor Sequencing Assay for Identification of Recent or Prior SARS-CoV-2 Infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.06.21249345
DO 10.1101/2021.01.06.21249345
A1 Dalai, Sudeb C.
A1 Dines, Jennifer N.
A1 Snyder, Thomas M.
A1 Gittelman, Rachel M.
A1 Eerkes, Tera
A1 Vaney, Pashmi
A1 Howard, Sally
A1 Akers, Kipp
A1 Skewis, Lynell
A1 Monteforte, Anthony
A1 Witte, Pam
A1 Wolf, Cristina
A1 Nesse, Hans
A1 Herndon, Megan
A1 Qadeer, Jia
A1 Duffy, Sarah
A1 Svejnoha, Emily
A1 Taromino, Caroline
A1 Kaplan, Ian M.
A1 Alsobrook, John
A1 Manley, Thomas
A1 Baldo, Lance
YR 2021
UL http://medrxiv.org/content/early/2021/01/08/2021.01.06.21249345.abstract
AB Background While diagnostic, therapeutic, and vaccine development in the COVID-19 pandemic has proceeded at unprecedented speed and scale, critical gaps remain in our understanding of the immune response to SARS-CoV-2. Current diagnostic strategies, including serology, have numerous limitations in addressing these gaps. Here we describe clinical performance of T- Detect™ COVID, the first reported assay to determine recent or prior SARS-CoV-2 infection based on T-cell receptor (TCR) sequencing and immune repertoire profiling from whole blood samples.Methods Methods for high-throughput immunosequencing of the TCRβ gene from blood specimens have been described1. We developed a statistical classifier showing high specificity for identifying prior SARS-CoV-2 infection2, utilizing >4,000 SARS-CoV-2-associated TCR sequences from 784 cases and 2,447 controls across 5 independent cohorts. The T-Detect COVID Assay comprises immunosequencing and classifier application to yield a qualitative positive or negative result. Several retrospective and prospective cohorts were enrolled to assess assay performance including primary and secondary Positive Percent Agreement (PPA; N=205, N=77); primary and secondary Negative Percent Agreement (NPA; N=87, N=79); PPA compared to serology (N=55); and pathogen cross-reactivity (N=38).Results T-Detect COVID demonstrated high PPA in subjects with prior PCR-confirmed SARS-CoV-2 infection (97.1% 15+ days from diagnosis; 94.5% 15+ days from symptom onset), high NPA (∼100%) in presumed or confirmed SARS-CoV-2 negative cases, equivalent or higher PPA than two commercial EUA serology tests, and no evidence of pathogen cross-reactivity.Conclusion T-Detect COVID is a novel T-cell immunosequencing assay demonstrating high clinical performance to identify recent or prior SARS-CoV-2 infection from standard blood samples. This assay can provide critical insights on the SARS-CoV-2 immune response, with potential implications for clinical management, risk stratification, surveillance, assessing protective immunity, and understanding long-term sequelae.Competing Interest StatementSCD declares employment and equity ownership with Adaptive Biotechnologies and employment with Stanford University School of Medicine. TM and LB declare leadership, employment, and equity ownership with Adaptive Biotechnologies. All other authors declare employment and equity ownership with Adaptive Biotechnologies.Clinical TrialNCT04583982, NCT04494893Funding StatementFunding was provided by Adaptive Biotechnologies.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All samples were collected pursuant to an Institutional Review Board (IRB)-approved clinical study protocol, ImmuneSense COVID-19 Study (PRO-00781/ADAP-007/WIRB#20202820/NCT04583982.) Residual samples collected under prospective study protocols obtained informed consent from participants under a separate protocol: ImmuneRACE (ADAP-006/WIRB# 20200625/NCT04494893). All other samples from cohorts described were collected as clinical remnant samples.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData requests may be submitted for consideration to: https://www.adaptivebiotech.com/medical-information-request/